Notice of allowance of US patent application for VAL001
Respiratorius announces that the patent application for the formulation of valproate that forms the basis of VAL001 has been approved through a formal Notice of Allowance from the US Patent and Trademark Office, USPTO.The patent application is the first concerning the VAL001 formulation for Respiratorius and claims a new oral formulation of sodium valproate for the pre-treatment of cancer. The priority date for the patent application is April 21, 2016, and is valid for at least 20 years from the priority date, which provides market exclusivity during this period. The corresponding